The pharmaceutical industry’s move toward increased U.S.-based manufacturing is changing the landscape of career ...

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies ...

The stock of Eli Lilly has a consensus Strong Buy rating among 19 Wall Street analysts. That rating is based on 16 Buy, two ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company ...

Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...

AbCellera's AI-driven drug discovery model hasn't translated into meaningful growth. Click here to read an analysis of ABCL ...

Eli Lilly closed at $1.87, ranked 34th in trading volume on July 22, 2025. BMO Capital remains bullish, reiterating a buy ...

Per the graph above, the Vanguard S&P 500 ETF has generated a total return of 647% since its inception in 2010. This equates to 14.5% annually. Assuming these returns keep up, a $200 monthly ...

Heritage Investors Management Corp has upped its game by purchasing an additional 2,647 shares of The Home Depot, bringing ...

ASTRAZENECA plans to spend US$50bn building manufacturing and research facilities in the US, following similar promises from ...